{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:20:32Z","timestamp":1782354032221,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY030838"],"award-info":[{"award-number":["R01EY030838"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000262","name":"Foundation Fighting Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002924","name":"Glaucoma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001641","name":"Glaucoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001641","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005242","name":"Universit\u00e9 de Montr\u00e9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["P30-026877"],"award-info":[{"award-number":["P30-026877"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.xops.2025.101032","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:19:21Z","timestamp":1765037961000},"page":"101032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase I Randomized Trial of Topical Insulin for Glaucoma: Safety and Efficacy Outcomes"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3475-7943","authenticated-orcid":false,"given":"Mariella","family":"Saludares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Wennberg-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Beykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-451X","authenticated-orcid":false,"given":"Tasneem Z.","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Nunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8674-6994","authenticated-orcid":false,"given":"QianQian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1430-0760","authenticated-orcid":false,"given":"Adriana","family":"Di Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1390-7360","authenticated-orcid":false,"given":"Jeffrey L.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2025.101032_bib1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/archopht.122.4.532","article-title":"Prevalence of open-angle glaucoma among adults in the United States","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.101032_bib2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","article-title":"The pathophysiology and treatment of glaucoma: a review","volume":"311","author":"Weinreb","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.xops.2025.101032_bib3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","article-title":"Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement","volume":"119","author":"Chang","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101032_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2025.101032_bib5","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.3390\/ijms22126403","article-title":"Role of insulin in health and disease: an update","volume":"22","author":"Rahman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xops.2025.101032_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1900\/RDS.2020.16.24","article-title":"Insulin-like growth factor and its therapeutic potential for diabetes complications - mechanisms and metabolic links: a review","volume":"16","author":"Biadgo","year":"2020","journal-title":"Rev Diabet Stud"},{"key":"10.1016\/j.xops.2025.101032_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/dmrr.919","article-title":"The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes","volume":"25","author":"Rajpathak","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.xops.2025.101032_bib8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.xops.2025.101032_bib9","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/brain\/awy142","article-title":"Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury","volume":"141","author":"Agostinone","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.xops.2025.101032_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adl5722","article-title":"Insulin restores retinal ganglion cell functional connectivity and promotes visual recovery in glaucoma","volume":"10","author":"El Hajji","year":"2024","journal-title":"Sci Adv"},{"key":"10.1016\/j.xops.2025.101032_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41746-024-01122-8","article-title":"A validated web-application (GFDC) for automatic classification of glaucomatous visual field defects using Hodapp-Parrish-Anderson criteria","volume":"7","author":"Thirunavukarasu","year":"2024","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.xops.2025.101032_bib12","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2017.04.035","article-title":"Evidence-based criteria for assessment of visual field reliability","volume":"124","author":"Yohannan","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2025.101032_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41433-020-1110-y","article-title":"Functional imaging of mitochondria in retinal diseases using flavoprotein fluorescence","volume":"35","author":"Chen","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.xops.2025.101032_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ogla.2021.12.006","article-title":"Mitochondrial dysfunction in primary open-angle glaucoma characterized by flavoprotein fluorescence at the optic nerve head","volume":"5","author":"Zhou","year":"2022","journal-title":"Ophthalmol Glaucoma"},{"issue":"1_suppl","key":"10.1016\/j.xops.2025.101032_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10915810600716653","article-title":"Final report on the safety assessment of sodium p -Chloro- m -Cresol, p -Chloro- m -Cresol, chlorothymol, mixed cresols, m -Cresol, o -Cresol, p -Cresol, isopropyl cresols, thymol, o -Cymen-5-ol, and Carvacrol1","volume":"25","year":"2006","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.xops.2025.101032_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1081-1206(10)60645-X","article-title":"Delayed-type hypersensitivity reaction to the meta-cresol component of insulin","volume":"99","author":"Kim","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.xops.2025.101032_bib17","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/jop.1994.10.683","article-title":"Insulin administration to the eyes of normoglycemic human volunteers","volume":"10","author":"Bartlett","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"10.1016\/j.xops.2025.101032_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/jop.1994.10.101","article-title":"Toxicity of insulin administered chronically to human eye in vivo","volume":"10","author":"Bartlett","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"10.1016\/j.xops.2025.101032_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/jop.1995.11.283","article-title":"Systemic absorption of insulin and glucagon applied topically to the eyes of rats and a diabetic dog","volume":"11","author":"Pillion","year":"1995","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2025.101032_bib20","first-page":"3021","article-title":"Systemic absorption of insulin delivered topically to the rat eye","volume":"32","author":"Pillion","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101032_bib21","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1111\/aos.14997","article-title":"Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea","volume":"100","author":"Diaz-Valle","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2025.101032_bib22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/ICO.0000000000002858","article-title":"Topical insulin-utility and results in refractory neurotrophic keratopathy in stages 2 and 3","volume":"41","author":"Soares","year":"2022","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2025.101032_bib23","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/ICO.0000000000001297","article-title":"Use of topical insulin to treat refractory neurotrophic corneal ulcers","volume":"36","author":"Wang","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.xops.2025.101032_bib24","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1167\/iovs.05-0301","article-title":"Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats","volume":"46","author":"Lambiase","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101032_bib25","first-page":"667","article-title":"Topical insulin protects against retinal ganglion cell loss in nonhuman primate model of experimental glaucoma","volume":"65","author":"Chaudhary","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101032_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jns.2006.08.012","article-title":"Imaging of the optic disc and retinal nerve fiber layer in acute optic neuritis","volume":"250","author":"Pro","year":"2006","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.xops.2025.101032_bib27","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1167\/iovs.07-1090","article-title":"Dao-Yi yu; time-dependent effects of elevated intraocular pressure on optic nerve head axonal transport and cytoskeleton proteins","volume":"49","author":"Balaratnasingam","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101032_bib28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1167\/iovs.16-20571","article-title":"Astrocytes in the optic nerve head of glaucomatous mice display a characteristic reactive phenotype","volume":"58","author":"Wang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101032_bib29","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.3390\/ijms22094672","article-title":"Insulin signaling as a therapeutic target in glaucomatous neurodegeneration","volume":"22","author":"Al Hussein Al Awamlh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xops.2025.101032_bib30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12035-012-8339-9","article-title":"Insulin in the brain: sources, localization and functions","volume":"47","author":"Ghasemi","year":"2013","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.xops.2025.101032_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuroscience.2015.05.072","article-title":"Impairment of insulin receptor substrate 1 signaling by insulin resistance inhibits neurite outgrowth and aggravates neuronal cell death","volume":"301","author":"Song","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.xops.2025.101032_bib32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xops.2025.101032_bib33","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1167\/iovs.08-3013","article-title":"Effect of CNTF on retinal ganglion cell survival in experimental glaucoma","volume":"50","author":"Pease","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101032_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.exer.2010.05.016","article-title":"Neurotrophic factor delivery as a protective treatment for glaucoma","volume":"93","author":"Johnson","year":"2011","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2025.101032_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1167\/iovs.66.4.48","article-title":"Targeted neuroprotection of retinal ganglion cells via AAV2-hSyn-NGF gene therapy in glaucoma models","volume":"66","author":"Zhu","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2025.101032_bib36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ajo.2021.11.002","article-title":"Phase 1b randomized controlled study of short course topical recombinant human nerve growth factor (rhNGF) for neuroenhancement in glaucoma: safety, tolerability, and efficacy measure outcomes","volume":"234","author":"Beykin","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2025.101032_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100298","article-title":"Phase I NT-501 ciliary neurotrophic factor implant trial for primary open-angle glaucoma: safety, neuroprotection, and neuroenhancement","volume":"3","author":"Goldberg","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2025.101032_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55345-x","article-title":"Sample size requirements of glaucoma clinical trials when using combined optical coherence tomography and visual field endpoints","volume":"9","author":"Wu","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2025.101032_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100290","article-title":"Safety and target engagement of complement C1q inhibitor ANX007 in neurodegenerative eye disease: results from phase I studies in glaucoma","volume":"3","author":"Sun","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.xops.2025.101032_bib40","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525003306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914525003306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T18:24:04Z","timestamp":1778523844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914525003306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2666914525003306"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2025.101032","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I Randomized Trial of Topical Insulin for Glaucoma: Safety and Efficacy Outcomes","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2025.101032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"101032"}}